|
1
|
Löwenberg B, Downing JR and Burnett A:
Acute myeloid leukemia. N Engl J Med. 341:1051–1062. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
NCCN Clinical Practice Guidelines in
Oncology: Acute Myeloid Leukemia. National Comprehensive Cancer
Network. version 2.2014. http://williams.medicine.wisc.edu/amlDecember
30–2015
|
|
3
|
Stein EM: Molecularly targeted therapies
for acute myeloid leukemia. Hematology Am Soc Hematol Educ Program.
2015:579–583. 2015.PubMed/NCBI
|
|
4
|
Xue YP, Bian SG, Meng QX, Mi YC and Yang
DG: Clinical observation of HAD regien in adult acute myeloid
leukemia treatment. Chin J Hematol. 16:59–61. 1995.
|
|
5
|
Löwenberg B, Pabst T, Vellenga E, van
Putten W, Schouten HC, Graux C, Ferrant A, Sonneveld P, Biemond BJ,
Gratwohl A, et al: Cytarabine dose for acute myeloid leukemia. N
Engl J Med. 364:1027–1036. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Löwenberg B: Sense and nonsense of
high-dose cytarabine for acute myeloid leukemia. Blood. 121:26–28.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fernandez HF, Sun Z, Yao X, Litzow MR,
Luger SM, Paietta EM, Racevskis J, Dewald GW, Ketterling RP,
Bennett JM, et al: Anthracycline dose intensification in acute
myeloid leukemia. N Engl J Med. 361:1249–1259. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gardin C, Chevret S, Pautas C, Turlure P,
Raffoux E, Thomas X, Quesnel B, de Revel T, de Botton S, Gachard N,
et al: Superior long-term outcome with idarubicin compared with
high-dose daunorubicin in patients with acute myeloid leukemia age
50 years and older. J Clin Oncol. 31:321–327. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pautas C, Merabet F, Thomas X, Raffoux E,
Gardin C, Corm S, Bourhis JH, Reman O, Turlure P, Contentin N, et
al: Randomized study of intensified anthracycline doses for
induction and recombinant interleukin-2 for maintenance in patients
with acute myeloid leukemia age 50 to 70 years: Results of the
ALFA-9801 study. J Clin Oncol. 28:808–814. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bishop JF, Matthews JP, Young GA,
Bradstock K and Lowenthal RM: Intensified induction chemotherapy
with high dose cytarabine and etoposide for acute myeloid leukemia:
A review and updated results of the Australian Leukemia Study
Group. Leuk Lymphoma. 28:315–327. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Holowiecki J, Grosicki S, Giebel S, Robak
T, Kyrcz-Krzemien S, Kuliczkowski K, Skotnicki AB, Hellmann A,
Sulek K, Dmoszynska A, et al: Cladribine, but not fludarabine,
added to daunorubicin and cytarabine during induction prolongs
survival of patients with acute myeloid leukemia: A multicenter,
randomized phase III study. J Clin Oncol. 30:2441–2448. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fresno M, Jimenéz A and Vázquez D:
Inhibition of translation in eukaryotic systems by harringtonine.
Eur J Biochem. 72:323–330. 1977. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gurel G, Blaha G, Moore PB and Steitz TA:
U2504 determines the species specificity of the A-site cleft
antibiotics: The structures of tiamulin, homoharringtonine, and
bruceantin bound to the ribosome. J Mol Biol. 389:146–156. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Baaske DM and Heinstein P: Cytotoxicity
and cell cycle specificity of homoharringtonine. Antimicrob Agents
Chemother. 12:298–300. 1977. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhou DC, Zittoun R and Marie JP:
Homoharringtonine: An effective new natural product in cancer
chemotherapy. Bull Cancer. 82:987–995. 1995.PubMed/NCBI
|
|
16
|
Cortes J, Lipton JH, Rea D, Digumarti R,
Chuah C, Nanda N, Benichou AC, Craig AR, Michallet M, Nicolini FE,
et al: Phase 2 study of subcutaneous omacetaxine mepesuccinate
after TKI failure in patients with chronic-phase CML with T315I
mutation. Blood. 120:2573–2580. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cortes J, Digumarti R, Parikh PM, Wetzler
M, Lipton JH, Hochhaus A, Craig AR, Benichou AC, Nicolini FE,
Kantarjian HM, et al: Phase 2 study of subcutaneous omacetaxine
mepesuccinate for chronic-phase chronic myeloid leukemia patients
resistant to or intolerant of tyrosine kinase inhibitors. Am J
Hematol. 88:350–354. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Alvandi F, Kwitkowski VE, Ko CW, Rothmann
MD, Ricci S, Saber H, Ghosh D, Brown J, Pfeiler E, Chikhale E, et
al: U.S. Food and drug administration approval summary: Omacetaxine
mepesuccinate as treatment for chronic myeloid leukemia.
Oncologist. 19:94–99. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jin J, Jiang DZ, Mai WY, Meng HT, Qian WB,
Tong HY, Huang J, Mao LP, Tong Y, Wang L, et al: Homoharringtonine
in combination with cytarabine and aclarubicin resulted in high
complete remission rate after the first induction therapy in
patients with de novo acute myeloid leukemia. Leukemia.
20:1361–1367. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jin J, Wang JX, Chen FF, Wu DP, Hu J, Zhou
JF, Hu JD, Wang JM, Li JY, Huang XJ, et al: Homoharringtonine-based
induction regimens for patients with de-novo acute myeloid
leukaemia: A multicentre, open-label, randomised, controlled phase
3 trial. Lancet Oncol. 14:599–608. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xiao Z, Xue H, Li R, Zhang L, Yu M and Hao
Y: The prognostic signifi cance of leukemic cells clearance
kinetics evaluation during the initial course of induction therapy
with HAD (homoharringtonine, cytosine arabinoside, daunorubicin) in
patients with de novo acute myeloid leukemia. Am J Hematol.
83:203–205. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Qin TJ, Xu ZF, Fang LW, Zhang HL, Zhang Y,
Wang JZ, Pan LJ, Hu NB and Xiao ZJ: Clinical study on combination
of homoharringtonine, ara-c and idarubicin induction for treatment
of newly diagnosed acute myeloid leukemia patients. Zhongguo Shi
Yan Xue Ye Xue Za Zhi. 19:1277–1282. 2011.(In Chinese). PubMed/NCBI
|
|
23
|
Vardiman JW, Thiele J, Arber DA, Brunning
RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM,
Hellström-Lindberg E, Tefferi A, et al: The 2008 revision of the
World Health Organization (WHO) classification of myeloid neoplasms
and acute leukemia: rationale and important changes. Blood.
114:937–951. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Schreck RR and Disteche CM: Chromosome
banding techniques. Curr Protoc Hum Genet Chapter.
4:Unit4.22001.
|
|
25
|
Bienz M, Ludwig M, Leibundgut EO, Mueller
BU, Ratschiller D, Solenthaler M, Fey MF and Pabst T: Risk
assessment in patients with acute myeloid leukemia and a normal
karyotype. Clin Cancer Res. 11:1416–1424. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bennett JM, Catovsky D, Daniel MT,
Flandrin G, Galton DA, Gralnick HR and Sultan C: Proposals for the
classification of the acute leukaemias. French-American-British
(FAB) co-operative group. Br J Haematol. 33:451–458. 1976.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
National Cancer: Institute: Common
Terminology Criteria for Adverse Events (CTCAE), . National Cancer
Institute, Division of Cancer Treatment and Diagnosis. version 3.0.
https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htmlDecember
28–2015
|
|
28
|
Zheng BG, Luo XS, Zhou YH, Zheng ZY, Shen
YP, Lin SY and Hu ZP: The treatment of HA regimen in 34 patients
with acute non-lymphocytic leukemia. Chin J Hematol. 10:405–406.
1989.
|
|
29
|
Fu YH and Liu YZ: 106 cases of acute
myeloid leukemia treated with HA or DA regimen. Hu Nan Yi Xue.
18:3902001.
|
|
30
|
Bian SG, Hao YS and Wang ZC: Study of the
treatment of adult acute non-lymphocytic leukemia. Chin J Hematol.
14:59–62. 1993.
|
|
31
|
Xiao Z, Xue H, Li R, Zhang L, Yu M and Hao
Y: The prognostic significance of leukemic cells clearance kinetics
evaluation during the initial course of induction therapy with HAD
(homoharringtonine, cytosine arabinoside, daunorubicin) in patients
with de novo acute myeloid leukemia. Am J Hematol. 83:203–205.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kantarjian H, O'Brien S, Jabbour E, Barnes
G, Pathak A and Cortes J: Effectiveness of homoharringtonine
(omacetaxine mepesuccinate) for treatment of acute myeloid
leukemia: A meta-analysis of Chinese studies. Clin Lymphoma Myeloma
Leuk. 15:13–21. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cai Z, Bao HY, Ludwig WD and Wuchter C:
Expression and significance of apoptosis protein inhibitor survivin
and XIAP, in patients with myelodysplastic syndromes and in the
cell line MUTZ-1. Zhonghua Xue Ye Xue Za Zhi. 25:26–30. 2004.(In
Chinese). PubMed/NCBI
|
|
34
|
Lu XY, Cao WK, Ye LL, Deng ZK, Zhang XH
and Li YF: Time rhythm of homoharringtonine inducing K562 cell
apoptosis and its mechanism. Zhongguo Shi Yan Xue Ye Xue Za Zhi.
22:712–716. 2014.(In Chinese). PubMed/NCBI
|
|
35
|
Zhang T, Shen S, Zhu Z, Lu S, Yin X, Zheng
J and Jin J: Homoharringtonine binds to and increases myosin-9 in
myeloid leukaemia. Br J Pharmacol. 173:212–221. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Slovak ML, Kopecky KJ, Cassileth PA,
Harrington DH, Theil KS, Mohamed A, Paietta E, Willman CL, Head DR,
Rowe JM, et al: Karyotypic analysis predicts outcome of
preremission and postremission therapy in adult acute myeloid
leukemia: A Southwest Oncology Group/Eastern Cooperative Oncology
Group Study. Blood. 96:4075–4083. 2000.PubMed/NCBI
|
|
37
|
Schlenk RF, Döhner K, Krauter J, Fröhling
S, Corbacioglu A, Bullinger L, Habdank M, Spath D, Morgan M, Benner
A, et al: Mutations and treatment outcome in cytogenetically normal
acute myeloid leukemia. N Engl J Med. 358:1909–1918. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Feldman E, Arlin Z, Ahmed T, Mittelman A,
Puccio C, Chun H, Cook P and Baskind P: Homoharringtonine in
combination with cytarabine for patients with acute myelogenous
leukemia. Leukemia. 6:1189–1191. 1992.PubMed/NCBI
|
|
39
|
Wu L, Li X, Chang C, Xu F, He Q, Wu D,
Zhang Z, Su J, Zhou L, Song L, et al: Efficacy and toxicity of
decitabine versus CHG regimen (low-dose cytarabine,
homoharringtonine and granulocyte colony-stimulating factor) in
patients with higher risk myelodysplastic syndrome: a retrospective
study. Leuk Lymphoma. 57:1367–1374. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chen C, Xu W and Yang J: Low-dose
homoharringtonine and cytarabine in combination with granulocyte
colony-stimulating factor for elderly patients with de novo acute
myeloid leukemia. Leuk Lymphoma. 56:141–146. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Hu X, Fu W, Wang L, Gao L, Lü S, Xi H, Qiu
H, Chen L, Chen J, Ni X, et al: HAG regimen improves survival in
adult patients with hypocellular acute myeloid leukemia.
Oncotarget. 7:3623–3634. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Daver N, Vega-Ruiz A, Kantarjian HM,
Estrov Z, Ferrajoli A, Kornblau S, Verstovsek S, Garcia-Manero G
and Cortes JE: A phase II open-label study of the intravenous
administration of homoharringtonine in the treatment of
myelodysplastic syndrome. Eur J Cancer Care (Engl). 22:605–611.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Nemunaitis J, Mita A, Stephenson J, Mita
MM, Sarantopoulos J, Padmanabhan-Iyer S, Nanda N, Gleich L,
Benichou AC and Craig A: Pharmacokinetic study of omacetaxine
mepesuccinate administered subcutaneously to patients with advanced
solid and hematologic tumors. Cancer Chemother Pharmacol. 71:35–41.
2013. View Article : Google Scholar : PubMed/NCBI
|
